Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations. Read why I maintain my buy ...

We recently published a list of 10 Best Very Cheap Stocks To Buy Right Now. In this article, we are going to take a look at where Pfizer Inc.

We can refer to full-year 2019 revenue of about $51 billion and the company's comments about potential revenue of more than ...

Total revenue increased by 32% to CHF 209m Operating profit tripled to CHF 61mOperating cash flow significantly increased to CHF 74mAd hoc ...

Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023) Strong year-end cash position of €168.3 million; Substantial clinical and regulatory p ...

Pfizer (PFE) is a pharmaceutical and biotechnology company valued at $145 billion by market capitalization. While the company ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

These 3 undervalued healthcare stocks are attractive today for their total return potential and potential long-term dividend ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...